Compare CUBI & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CUBI | DNLI |
|---|---|---|
| Founded | 1994 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.4B |
| IPO Year | 2010 | 2017 |
| Metric | CUBI | DNLI |
|---|---|---|
| Price | $74.44 | $18.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 20 |
| Target Price | ★ $93.55 | $36.06 |
| AVG Volume (30 Days) | 243.4K | ★ 1.7M |
| Earning Date | 10-22-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.99 | N/A |
| EPS | ★ 4.02 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.60 | N/A |
| Revenue Next Year | $11.86 | $156.11 |
| P/E Ratio | $18.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $59.34 | $13.75 |
| 52 Week High | $84.38 | $27.30 |
| Indicator | CUBI | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 37.67 | 28.34 |
| Support Level | $72.04 | $18.38 |
| Resistance Level | $79.75 | $20.84 |
| Average True Range (ATR) | 1.57 | 0.81 |
| MACD | -0.20 | -0.08 |
| Stochastic Oscillator | 36.26 | 8.45 |
Customers Bancorp Inc is a bank holding company conducting banking activities through its wholly owned subsidiary, Customers Bank. The Bank provides commercial and consumer customers the stability of a regulated financial institution supported by risk management. It serves commercial and corporate businesses nationwide, including healthcare, real estate, specialty finance, fund finance, technology and venture capital banking, mortgage finance and commercial equipment financing, and provides payments and treasury services. The Bank also serves consumers through its branch network, offering residential mortgages and personal loan and deposit products, including Banking-as-a-Service, with services delivered predominantly in Southeastern and Central Pennsylvania, New York, and other states.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.